San Diego, October 15th / PRNewswire / -- QuidelOrtho Corporation (Nasdaq ticker: QDEL, hereinafter referred to as “QuidelOrtho”) announced today that the company's Board of Directors Compensation Committee has approved the granting of equity incentives (“onboarding incentive grants”) to two newly hired non-executive employees. These grants are in accordance with the company's 2026 Onboarding Incentive Plan and serve as an important motivation for the employees to join the company, in compliance with Nasdaq Listing Rule 5635(c)(4).
The 2026 Onboarding Incentive Plan is intended solely for individuals who were not previously QuidelOrtho employees, or those who rejoin the company after their official resignation period. It serves as an important incentive for them to join QuidelOrtho, in accordance with NASDAQ Listing Rule 5635(c)(4).
This incentive grant upon employment includes restricted stock units (RSUs), corresponding to a total of 50,323 shares of the company's common stock. The grant date for RSUs is October 15, 2026, and the shares will vest in equal portions on the first, second, and third anniversaries from the grant date, provided that the employee remains employed with the company until those respective vesting dates. RSUs is subject to the 2026 employment incentive plan as well as the terms of the RSU grant agreement that covers each incentive grant upon employment.
QuidelOrtho indicates that the company is committed to advancing diagnostic technologies to drive a healthier future. For more information, please visit quidelortho.com, and follow QuidelOrtho on LinkedIn, Facebook, and X.
About QuidelOrtho Corporation
QuidelOrtho Corporation (Nasdaq ticker: QDEL) possesses expertise in clinical chemistry, immunoassay, immunohematology, and molecular testing, and is a global leader in diagnostic solutions. The company is committed to providing fast, accurate, and reliable test results to help improve patient outcomes – from point-of-care tests to hospitals, from laboratories to clinics. Building on a tradition of innovation, QuidelOrtho collaborates with healthcare providers to advance diagnostic technologies, connecting insights with solutions to define clearer paths for more informed decision-making and better patient care.
Investor Contact:
Sanjeev SharmaVice President of Investor Relations[ email protected ]Media contact:
Stephanie KleeweinSenior Corporate Communications and PR Manager[ email protected ]
